Cancer Immunology, Immunotherapy View Homepage


Ontology type: schema:Periodical     


Journal Info

START YEAR

1982

PUBLISHER

Springer Berlin Heidelberg

LANGUAGE

en

HOMEPAGE

https://link.springer.com/journal/262

Recent publications latest 20 shown

  • 2022-05-12 In vitro and in vivo evaluation of DC-targeting PLGA nanoparticles encapsulating heparanase CD4+ and CD8+ T-cell epitopes for cancer immunotherapy
  • 2022-05-07 Targeting tumor extracellular matrix activates the tumor-draining lymph nodes
  • 2022-05-06 Invariant NKT cell-augmented GM-CSF-secreting tumor vaccine is effective in advanced prostate cancer model
  • 2022-05-04 Inability of ovarian cancers to upregulate their MHC-class I surface expression marks their aggressiveness and increased susceptibility to NK cell-mediated cytotoxicity
  • 2022-04-27 First-in-human study of WT1 recombinant protein vaccination in elderly patients with AML in remission: a single-center experience
  • 2022-04-26 Incidence of hepatotoxicity associated with addition of immune checkpoint blockade to systemic solid tumor therapy: a meta-analysis of phase 3 randomized controlled trials
  • 2022-04-26 Immune activation of the monocyte-derived dendritic cells using patients own circulating tumor cells
  • 2022-04-25 Correction to: Functional antigen processing and presentation mechanism as a prerequisite factor of response to treatment with dendritic cell vaccines and anti-PD-1 in preclinical murine LLC1 and GL261 tumor models
  • 2022-04-23 Tcf-1 protects anti-tumor TCR-engineered CD8+ T-cells from GzmB mediated self-destruction
  • 2022-04-21 Opening up new VISTAs: V-domain immunoglobulin suppressor of T cell activation (VISTA) targeted near-infrared photoimmunotherapy (NIR-PIT) for enhancing host immunity against cancers
  • 2022-04-20 Clinical and molecular correlates of response to immune checkpoint blockade in urothelial carcinoma with liver metastasis
  • 2022-04-19 Chimeric antigen receptor clustering via cysteines enhances T-cell efficacy against tumor
  • 2022-04-18 Gene expression profile of high PD-L1 non-small cell lung cancers refractory to pembrolizumab
  • 2022-04-18 Establishment of a mechanism-based in vitro coculture assay for evaluating the efficacy of immune checkpoint inhibitors
  • 2022-04-16 Serial interferon-gamma release assay in lung cancer patients receiving immune checkpoint inhibitors: a prospective cohort study
  • 2022-04-16 Role of the cGAS-STING pathway in regulating the tumor-immune microenvironment in dMMR/MSI colorectal cancer
  • 2022-04-16 Prognostic significance of NY-ESO-1 antigen and PIGR expression in esophageal tumors of CHP-NY-ESO-1-vaccinated patients as adjuvant therapy
  • 2022-04-15 The soluble form of CD160 acts as a tumor mediator of immune escape in melanoma
  • 2022-04-15 Tumor-derived exosomes drive pre-metastatic niche formation in lung via modulating CCL1+ fibroblast and CCR8+ Treg cell interactions
  • 2022-04-04 Evaluation of the efficacy and safety of TAS0313 in adults with recurrent glioblastoma
  • JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "contentRating": [
          {
            "author": "snip", 
            "ratingValue": "1.2259999513626099", 
            "type": "Rating"
          }, 
          {
            "author": "sjr", 
            "ratingValue": "2.3889999389648438", 
            "type": "Rating"
          }
        ], 
        "description": "

    Since its inception in 1976, Cancer Immunology, Immunotherapy (CII) has reported significant advances in the field of tumor immunology.\u00a0 The journal serves as a forum for new concepts and advances in basic, translational, and clinical cancer immunology and immunotherapy. CII is keen to publish broad-ranging ideas and reviews, results which extend or challenge established paradigms, as well as negative studies which fail to reproduce experiments that support current paradigms, and papers that do succeed in reproducing others\u2019 results in different contexts. Cll is especially interested in papers describing clinical trial designs and outcome regardless of whether they met their designated endpoints or not, and particularly those shedding light on immunological mechanisms.

    CII is affiliated with the Association for Cancer Immunotherapy (CIMT), Canadian Cancer Immunotherapy Consortium (CCIC), The Japanese Association for Cancer Immunology (JACI), Network Italiano per la Bioterapia dei Tumori (NIBIT), and\u00a0Sociedad Espa\u00f1ola de Inmunologia-Grupo Espa\u00f1ola de\u00a0InmunoTerapia\u00a0(SEI-GEIT).

    CIMT: http://www.cimt.eu/home

    CCIC: http://www.immunotherapycancer.ca/

    JACI: http://www.jaci.jp/eng/index.html

    NIBIT: http://www.nibit.org/index.php

    SEI-GEIT: http://www.inmunologia.org/grupos/home.php?UpOm5=M&Upfqym5uom=GK\u00a0\u00a0

    CITIM: http://www.canceritim.org", "editor": [ { "familyName": "Dong", "givenName": "Haidong", "type": "Person" } ], "id": "sg:journal.1096240", "inLanguage": [ "en" ], "isAccessibleForFree": false, "issn": [ "0340-7004", "1432-0851" ], "license": "Hybrid", "name": "Cancer Immunology, Immunotherapy", "productId": [ { "name": "dimensions_id", "type": "PropertyValue", "value": [ "96240" ] }, { "name": "lccn_id", "type": "PropertyValue", "value": [ "sn 84010370" ] }, { "name": "nlm_unique_id", "type": "PropertyValue", "value": [ "8605732" ] }, { "name": "nsd_ids_id", "type": "PropertyValue", "value": [ "339854" ] }, { "name": "era_ids_id", "type": "PropertyValue", "value": [ "15463" ] } ], "publisher": { "name": "Springer Berlin Heidelberg", "type": "Organization" }, "publisherImprint": "Springer", "sameAs": [ "https://app.dimensions.ai/discover/publication?and_facet_source_title=jour.1096240" ], "sdDataset": "journals", "sdDatePublished": "2022-05-20T07:52", "sdLicense": "https://scigraph.springernature.com/explorer/license/", "sdPublisher": { "name": "Springer Nature - SN SciGraph project", "type": "Organization" }, "sdSource": "s3://com-springernature-scigraph/baseset/20220519/entities/gbq_results/journal/journal_0.jsonl", "startYear": "1982", "type": "Periodical", "url": "https://link.springer.com/journal/262" } ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/journal.1096240'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/journal.1096240'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/journal.1096240'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/journal.1096240'


     

    This table displays all metadata directly associated to this object as RDF triples.

    60 TRIPLES      20 PREDICATES      27 URIs      23 LITERALS      10 BLANK NODES

    Subject Predicate Object
    1 sg:journal.1096240 schema:contentRating N3903b7235cc7404987d076f86ea9123d
    2 N4952d1b5cdbb4c799a0e0e7ed47076f6
    3 schema:description <p>Since its inception in 1976, <i>Cancer Immunology, Immunotherapy</i> (CII) has reported significant advances in the field of tumor immunology.  The journal serves as a forum for new concepts and advances in basic, translational, and clinical cancer immunology and immunotherapy. CII is keen to publish broad-ranging ideas and reviews, results which extend or challenge established paradigms, as well as negative studies which fail to reproduce experiments that support current paradigms, and papers that do succeed in reproducing others’ results in different contexts. Cll is especially interested in papers describing clinical trial designs and outcome regardless of whether they met their designated endpoints or not, and particularly those shedding light on immunological mechanisms. </p><p>CII is affiliated with the <i>Association for Cancer Immunotherapy (CIMT)</i>,<i> Canadian Cancer Immunotherapy Consortium (CCIC)</i>, <i>The Japanese Association for Cancer Immunology (JACI), Network Italiano per la Bioterapia dei Tumori (NIBIT</i>),<i> </i>and <i>Sociedad Española de Inmunologia-Grupo Española de InmunoTerapia (SEI-GEIT)</i>.</p><p>CIMT: http://www.cimt.eu/home</p><p>CCIC: http://www.immunotherapycancer.ca/</p><p>JACI: http://www.jaci.jp/eng/index.html</p><p>NIBIT: http://www.nibit.org/index.php</p><p>SEI-GEIT: http://www.inmunologia.org/grupos/home.php?UpOm5=M&amp;Upfqym5uom=GK  </p>CITIM: http://www.canceritim.org
    4 schema:editor Ndac2ee50afff431ebc904e830486e647
    5 schema:inLanguage en
    6 schema:isAccessibleForFree false
    7 schema:issn 0340-7004
    8 1432-0851
    9 schema:license Hybrid
    10 schema:name Cancer Immunology, Immunotherapy
    11 schema:productId N3c3c687468bf45258161a1e4114708ef
    12 N45663a5cc15c49b59e3a7e6c1b6cf426
    13 N5686f863319b48ffae495f5dd0cb5fce
    14 N93661766174b4fc6a30612bf8e18ad10
    15 Nb6054bb525a044db929da2789db0d66b
    16 schema:publisher N0a0594e5a04c432db5f96e69cab570e2
    17 schema:publisherImprint Springer
    18 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_source_title=jour.1096240
    19 schema:sdDatePublished 2022-05-20T07:52
    20 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    21 schema:sdPublisher N3551462f1c2746389f6f32a902f983b1
    22 schema:startYear 1982
    23 schema:url https://link.springer.com/journal/262
    24 sgo:license sg:explorer/license/
    25 sgo:sdDataset journals
    26 rdf:type schema:Periodical
    27 N0a0594e5a04c432db5f96e69cab570e2 schema:name Springer Berlin Heidelberg
    28 rdf:type schema:Organization
    29 N0d351d778b714673b1c8b0a25d3638a2 rdf:first sjr
    30 rdf:rest rdf:nil
    31 N3551462f1c2746389f6f32a902f983b1 schema:name Springer Nature - SN SciGraph project
    32 rdf:type schema:Organization
    33 N3903b7235cc7404987d076f86ea9123d schema:author Nbf1da8acecae41a7a22e8b042a6a80c5
    34 schema:ratingValue 1.2259999513626099
    35 rdf:type schema:Rating
    36 N3c3c687468bf45258161a1e4114708ef schema:name dimensions_id
    37 schema:value 96240
    38 rdf:type schema:PropertyValue
    39 N45663a5cc15c49b59e3a7e6c1b6cf426 schema:name lccn_id
    40 schema:value sn 84010370
    41 rdf:type schema:PropertyValue
    42 N4952d1b5cdbb4c799a0e0e7ed47076f6 schema:author N0d351d778b714673b1c8b0a25d3638a2
    43 schema:ratingValue 2.3889999389648438
    44 rdf:type schema:Rating
    45 N5686f863319b48ffae495f5dd0cb5fce schema:name era_ids_id
    46 schema:value 15463
    47 rdf:type schema:PropertyValue
    48 N6a81f7ccf76b4c7ebad41df2d66bf4ea schema:familyName Dong
    49 schema:givenName Haidong
    50 rdf:type schema:Person
    51 N93661766174b4fc6a30612bf8e18ad10 schema:name nsd_ids_id
    52 schema:value 339854
    53 rdf:type schema:PropertyValue
    54 Nb6054bb525a044db929da2789db0d66b schema:name nlm_unique_id
    55 schema:value 8605732
    56 rdf:type schema:PropertyValue
    57 Nbf1da8acecae41a7a22e8b042a6a80c5 rdf:first snip
    58 rdf:rest rdf:nil
    59 Ndac2ee50afff431ebc904e830486e647 rdf:first N6a81f7ccf76b4c7ebad41df2d66bf4ea
    60 rdf:rest rdf:nil
     




    Preview window. Press ESC to close (or click here)


    ...